Evolution of multi-drug resistant hepatitis B virus during sequential therapy (Q45412758)

14 December 2017

Evolution of multi-drug resistant hepatitis B virus during sequential therapy (English)

1 reference

14 December 2017

multiple drug resistance

1 reference

1 reference

1 reference

Hyung Joon Yim

1

1 reference

14 December 2017

Munira Hussain

2

1 reference

14 December 2017

Ying Liu

3

1 reference

14 December 2017

Stephen N Wong

4

1 reference

14 December 2017

Scott K Fung

5

1 reference

14 December 2017

Anna S F Lok

6

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

14 December 2017

1 reference

14 December 2017

44

1 reference

14 December 2017

3

1 reference

14 December 2017

703-712

1 reference

Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients

14 December 2017

1 reference

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

7 January 2021

Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

1 reference

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

7 January 2021

Hepatitis B virus variants in patients receiving lamivudine treatment with breakthrough hepatitis evaluated by serial viral loads and full-length viral sequences

1 reference

7 January 2021

Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation

1 reference

7 January 2021

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

7 January 2021

Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis

1 reference

7 January 2021

Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants

1 reference

7 January 2021

Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy

1 reference

7 January 2021

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

1 reference

7 January 2021

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

7 January 2021

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

1 reference

7 January 2021

Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis

1 reference

7 January 2021

Hepatitis B virus surface mutations associated with infection after liver transplantation

1 reference

7 January 2021

Vaccine-induced escape mutant of hepatitis B virus

1 reference

7 January 2021

Loss of the common "A" determinant of hepatitis B surface antigen by a vaccine-induced escape mutant

1 reference

7 January 2021

Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy

1 reference

7 January 2021

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

1 reference

7 January 2021

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.

1 reference

7 January 2021

Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation

1 reference

7 January 2021

Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy.

1 reference

7 January 2021

Colinearity of Reverse Transcriptase Inhibitor Resistance Mutations Detected by Population-Based Sequencing

1 reference

7 January 2021

Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy

1 reference

7 January 2021

Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region

1 reference

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

7 January 2021

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

1 reference

7 January 2021

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

1 reference

7 January 2021

The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus

1 reference

7 January 2021

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

1 reference

7 January 2021

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

7 January 2021

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

1 reference

7 January 2021

Low dynamic state of viral competition in a chronic avian hepadnavirus infection

1 reference

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

7 January 2021

The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.

1 reference

7 January 2021

Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21290

1 reference

14 December 2017

1 reference